Hannah Valantine | |
|---|---|
 Hannah Valantine in 2020 | |
| Born | |
| Education | MBBS, St. George's Hospital Medical School |
| Occupation | National Institutes of Health Chief Officer for Scientific Workforce Diversity |
Dr. Hannah Valantine is the Chief Officer for Scientific Workforce Diversity at the United States National Institutes of Health. [1]
Valantine was born in The Gambia and lived in Banjul as a child. When her father was selected as the Gambian High Commissioner to the United Kingdom, she and her family moved to London. [2] She studied biochemistry at Chelsea College, London University and graduated from medical school at St. George's Hospital Medical School in 1978. [3]
After medical school Valantine performed post-graduate work in cardiology at the Brompton Hospital and Hammersmith Hospital in London. [1] She recalls that her decision to enter this field elicited skepticism from colleagues, [2] as only two other women cardiologists worked in the UK at the time. [4] After her residencies in the U.K., she became a fellow at Stanford and worked with Norman Shumway, a pioneer in the field of heart transplants. [1] She became a professor of cardiovascular medicine at the Stanford University School of Medicine in 1989 and reached full professor rank in 2001. [3]
Valantine became SUMC's Senior Associate Dean for Diversity and Faculty Development in 2005. [5] On taking this role, she cited the importance of mentorship and social engagement in developing the careers of young faculty [2] and emphasized her experience as a working mother in shaping her advice to young scientists. [3] During the 2009–10 academic year, Valantine was a Faculty Research Fellow at Stanford's Clayman Institute for Gender Research. [6] She was selected in 2010 as one of six recipients of NIH Pathfinder Awards, which were intended for the study of women's underrepresentation in biomedical faculty positions in the United States. [7]
Valantine describes her pursuit of innovation as the foundation of her professional career - innovation in heart transplant and innovation in efforts to diversify the biomedical research workforce. [8]
In 2014, NIH Director Francis Collins announced Valantine's appointment as NIH's first Chief Officer for Scientific Workforce Diversity, a new position whose entire focus is diversity in biomedicine. [1] Among her accomplishments in this position is the 2014 award of nearly $31 million to develop methods for outreach and career development targeted toward members of demographic groups underrepresented among professional scientists. [9]
Under Valantine's leadership, the racial gap in rates of NIH applications and awards to projects led by African-American researchers has been practically, and in some cases entirely, eliminated, with increases of up to 142% in some award areas. Similar trends are apparent for Hispanic/Latinx scientists. Valantine also developed the NIH Distinguished Scholars Program, which aims to increase diversity among tenure-track researchers in intramural research programs. [10] This program reduces barriers to recruitment of cohorts of principal investigators from underrepresented groups in biomedical research such as people of color, individuals with disabilities, and women. [11]
Valantine also leads the Laboratory of Transplantation Genomics at the National Heart, Lung, and Blood Institute in Bethesda, Maryland, focusing on heart transplant rejection. [12]
The University of California, San Francisco (UCSF) is a public land-grant research university in San Francisco, California. It is part of the University of California system and is dedicated entirely to health science and life science. It conducts research and teaching in medical and biological sciences.
The National Heart, Lung, and Blood Institute (NHLBI) is the third largest Institute of the National Institutes of Health, located in Bethesda, Maryland, United States. It is tasked with allocating about $3.6 billion in FY 2020 in tax revenue to advancing the understanding of the following issues: development and progression of disease, diagnosis of disease, treatment of disease, disease prevention, reduction of health care disparities within the American population, and advancing the effectiveness of the US medical system. NHLBI's Director is Gary H. Gibbons (2012–present).
The Duke University School of Medicine, commonly known as Duke Med, is the medical school of Duke University. It is located in the Collegiate Gothic-style West Campus of Duke University in Durham, North Carolina. The School of Medicine, along with the Duke University School of Nursing, Duke University Hospital, Duke Regional Hospital, Duke Children's Hospital, Duke Raleigh Hospital, and other affiliated hospitals, clinics, and laboratories, make up the Duke University Health System. Established in 1925 by James B. Duke, the School of Medicine has earned its reputation as an integral part of one of the world's foremost patient care and biomedical research institutions.
Eva Lucille Feldman, M.D., Ph.D., F.A.A.N., F.A.N.A. is an American physician-scientist and one of the world’s leading authorities on neurodegenerative disease. Currently, she serves as the Russell N. DeJong Professor of Neurology at the University of Michigan, as well as Director of the NeuroNetwork for Emerging Therapies and ALS Center of Excellence at Michigan Medicine. She was also recently named the James W. Albers Distinguished University Professor of Neurology.
Joe G. N. "Skip" Garcia is an American pulmonary scientist, physician and academician.
Susan Shurin is a senior adviser at the National Cancer Institute. From 2006–2014, she served as Deputy and Acting Director of the National Heart, Lung, and Blood Institute (NHLBI) [NHLBI.nih.gov] at the National Institutes of Health [nih.gov] (NIH).
Norman Edward Shumway was a pioneer of heart surgery at Stanford University. He was the 67th president of the American Association for Thoracic Surgery and the first to perform an adult human to human heart transplantation in the United States.
Vivian Winona Pinn is an American physician-scientist and pathologist known for her advocacy of women's health issues and concerns, particularly for ensuring that federally funded medical studies include female patients, and well as encouraging women to follow medical and scientific careers. She served as associate director for research on women's health at the National Institutes of Health (NIH), concurrently was the inaugural director of NIH's Office of Research on Women's Health. Pinn previously taught at Harvard University, Tufts University, and Howard University College of Medicine. Since retiring from NIH in 2011, Pinn has continued working as a senior scientist emerita at the Fogarty International Center.
Gary H. Gibbons is an American cardiologist and the current director of the National Heart, Lung, and Blood Institute.
A physician-scientist is traditionally a holder of a medical degree and a doctor of philosophy also known as an MD-PhD. Compared to other clinicians, physician-scientists invest significant time and professional effort in scientific research and spend correspondingly less time in direct clinical practice with ratios of research to clinical time ranging from 50/50 to 80/20. Physician-scientists are often employed by academic or research institutions where they drive innovation across a wide range of medical specialties and may also use their extensive training to focus their clinical practices on specialized patient populations, such as those with rare genetic diseases or cancers. Although they are a minority of both practicing physicians and active research scientists, physician-scientists are often cited as playing a critical role in translational medicine and clinical research by adapting biomedical research findings to health care applications. Over time, the term physician scientist has expanded to holders of other clinical degrees—such as nurses, dentists, and veterinarians— who are also included by the United States National Institutes of Health in its studies of the physician-scientist workforce (PSW).
Helen Haskell Hobbs, M.D., is a professor at the University of Texas Southwestern Medical Center, and a Howard Hughes Medical Institute Investigator, who won a 2016 Breakthrough Prize in Life Sciences and the 2018 Harrington Prize for Innovation in Medicine. She and Jonathan C. Cohen found that people with hypomorphic PCSK9 mutations had lower LDL-cholesterol levels and were almost immune to heart disease. This finding led to the development of a new class of cholesterol-lowering drugs that mimic the effects of the PCSK9 mutations. She and Jonathan Cohen also identified the first genetic risk factor for fatty liver disease, a burgeoning health problem that can lead to cirrhosis and liver cancer. Their laboratory has shown that mutation in PNPLA3 causes accumulation of PNPLA3 on lipid droplets, which compromises the mobilization of triglycerides from liver cells. She sits on the Board of Directors at Pfizer.
Joan Y. Reede is an American physician. She is Harvard Medical School's inaugural dean for diversity and community partnership, and a member of the National Academy of Medicine. She is known for creating programs that mentor and support minority physicians and female physicians. Alumni of her programs have created a 501(c)(3) organization called The Reede Scholars in her honor.
Roderic Ivan Pettigrew is an American physicist, engineer, and physician who is CEO of EnHealth and Executive Dean for EnMed at Texas A&M University. From 2002-November 2017, he was the founding director of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) at the National Institutes of Health (NIH). He is a pioneer and world expert in cardiovascular magnetic resonance imaging (MRI).
Phyllis C. Zee is the Benjamin and Virginia T. Boshes Professor in Neurology, the director of the Center for Circadian and Sleep Medicine (CCSM) and the chief of the Division of Sleep Medicine (neurology) at the Feinberg School of Medicine, Northwestern University, Chicago. She is also the medical director of Sleep Disorders Center at Northwestern Memorial Hospital.
JoAnn Trejo is an American pharmacologist, cell biologist, a professor, and also an assistant vice chancellor in the department of health sciences faculty affairs in the Department of Pharmacology at the School of Medicine at University of California, San Diego. She is also the assistant vice chancellor for Health Sciences Faculty Affairs. Trejo studies cell signalling by protease-activated G protein-coupled receptors (GPCRs). She is also actively involved in mentoring, education and outreach activities to increase the diversity of science.
Stephanie L. Constant is an American immunologist and science administrator. She was an associate professor at George Washington University and a scientific review officer at National Heart, Lung, and Blood Institute before becoming chief of the National Institute of General Medical Sciences Office of Scientific Review in 2017.
Elba E. Serrano is a neuroscientist and biophysicist who holds a position as a Regent's Professor of Biology at New Mexico State University.
Sherilynn Black is an American neuroscientist, the Associate Vice Provost for Faculty Advancement, as well as an assistant professor of the practice of medical education at Duke University in Durham, North Carolina. Black's research focuses on social neuroscience and developing interventions to promote diversity in academia. Black has been widely recognized for her commitment to faculty development and advancement and holds national appointments with the National Academy of Sciences, Engineering, and Medicine, the National Institutes of Health, the Howard Hughes Medical Institute, the American Association of Medical Colleges, The Burroughs Wellcome Fund, and the Society for Neuroscience.
Michael S. Lauer is an American cardiologist and physician-scientist. He is the deputy director for extramural research at the National Institutes of Health (NIH).
Courtney D. Fitzhugh is an American hematologist-oncologist and scientist. She is a clinical researcher and head of the laboratory of early sickle cell mortality prevention at the National Heart, Lung, and Blood Institute.
| International | |
|---|---|
| National | |
